Skip to main content
. Author manuscript; available in PMC: 2009 Nov 25.
Published in final edited form as: J Med Virol. 2009 Jan;81(1):65–74. doi: 10.1002/jmv.21360

Table 3.

IgG Subclass Distribution of anti-AAV2 Capsid Antibodies Following Hepatic Artery Administration of AAV2-hFIX Vector

Subject A (dose 8×1010 vg/kg)
Time Point IgG11 IgG21 IgG31 IgG41 IgM1 Neutralizing Titer2,3
Baseline 0 0 0 0 253 ND
Day 2 0 0 0 0 269 ND
Day 7 20697 433 874 197 1319 1:316 – 1:3.1×103
Week 3 25698 1548 0 312 1412 1:103 – 1:104
Week 6 28864 1073 429 212 1716 1:103 – 1:104
Week 16 29910 1366 843 337 1972 1:316 – 1:1000
Subject B (dose 8×1010 vg/kg)
Time Point IgG11 IgG21 IgG31 IgG41 IgM1 Neutralizing Titer2,3
Baseline 0 0 0 162 0 1:2
Day 2 0 0 0 0 0 ND
Day 7 0 0 0 26 0 1:10 – 1:31
Week 2 0 0 0 0 0 1:10 – 1:31
Week 4 0 0 0 0 0 ND
Week 8 9916 1904 0 0 343 ND
Subject D (dose 4×1011 vg/kg)
Time Point IgG11 IgG21 IgG31 IgG41 IgM1 Neutralizing Titer2,3
Baseline 0 0 0 61 228 1:11
Week 1 0 0 108 95 414 <1:100
Week 2 0 510 0 299 795 1:100 – 1:316
Week 3 6950 672 0 8 1346 1:3.1×103 – 1:105
Week 5 27289 481 1227 45 819 1:3.1×103 – 1:105
Week 12 35274 1078 3507 54 956 ND
Subject F (dose 2×1012 vg/kg)
Time Point IgG11 IgG21 IgG31 IgG41 IgM1 Neutralizing Titer2,3
Baseline 4096 0 674 56 228 1:17
Week 5 5083 0 1284 1 468 1:3.1×104 –1:106
Week 6 5404 0 1492 82 535 ND
Week 7 4605 0 1485 0 269 ND
Week 8 5285 0 1433 0 401 ND
Week 16 5538 453 1963 0 415 ND
1

Values shown represent antibody concentrations in ng/mL.

2

Neutralizing titer represents the highest dilution at which greater than or equal to 50% transduction occurs compared to controls.

3

These data were previously published [Manno et al., 2006] and are added here for comparison.